Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis

Company Overview

Galmed Pharmaceuticals Ltd. is an Israeli clinical-stage biopharmaceutical company focused on developing treatments for liver and metabolic diseases. The company’s research has centered on nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease associated with fat accumulation and inflammation.

Galmed’s lead product candidate has been aramchol, an orally administered synthetic conjugate of a fatty acid and bile acid. The company has evaluated aramchol for its potential to reduce liver fat and fibrosis, or scarring, in patients with NASH and related conditions. Galmed has also explored additional applications and combination-treatment strategies involving metabolic and liver disorders.

Founded in Israel, Galmed has conducted research and clinical-development activities in Israel, the United States and other international markets through clinical trials and regulatory interactions. The company has historically been led by founder and longtime chief executive officer Allen Baharaff. Galmed’s development programs and corporate status have changed over time, so investors should consult the company’s latest regulatory filings for current information about its pipeline, operations and leadership.

Key Stats

• Today's Range: $3.82 to $4.63
• 50-Day Range: $3.83 to $4.97
• 52-Week Range: $3.29 to $13.20
• Volume: 302,067 shs
• Average Volume: 52,894 shs
• Market Capitalization: $4.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Galmed Pharmaceuticals Stock Analysis - MarketRank™

Galmed Pharmaceuticals scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Galmed Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Galmed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Galmed Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Galmed Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Galmed Pharmaceuticals has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.35% of the float of Galmed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Galmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Galmed Pharmaceuticals has recently decreased by 47.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Galmed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Galmed Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 9/02/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GLMD
• CIK: 1595353
• Web: www.galmedpharma.com
• Phone: (723) 693-8448
• Fax: 972-3693-8447
• Employees: 20
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): ($15.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.68%
• Return on Assets: -60.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.16
• Quick Ratio: 4.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $23.04 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 1,042,000
• Free Float: 836,000
• Market Cap: $4.78 million
• Optionable: Not Optionable
• Beta: 0.67